Fas ligand and the fate of antitumour cytotoxic T lymphocytes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition.Cell death & disease · 2024
   Article
2. Understanding the Effects of Age and T-Cell Differentiation on COVID-19 Severity: Implicating a Fas/FasL-mediated Feed-Forward Controller of T-Cell Differentiation.Frontiers in immunology · 2022
   Article
3. The CD8Microbiology and molecular biology reviews : MMBR · 2021
   Review
4. The paratumoral immune cell signature reveals the potential for the implementation of immunotherapy in esophageal carcinoma patients.Journal of cancer research and clinical oncology · 2020
   Article
5. Akt-Fas to Quell Aberrant T Cell Differentiation and Apoptosis in Covid-19.Frontiers in immunology · 2020
   Review
6. Distributed Adaptive Search in T Cells: Lessons From Ants.Frontiers in immunology · 2019
   Review
7. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.Journal of clinical immunology · 2018
   Review
8. STAT5B: A Differential Regulator of the Life and Death of CD4Journal of immunology (Baltimore, Md. : 1950) · 2018
   Article
9. FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors.Molecular cancer · 2010
   Article
10. All in the head: obstacles for immune rejection of brain tumours.Immunology · 2002
    Review

Corrections and comments

• Comment on
  Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.2002

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as